Latest Breaking News On - Department of hematology oncology - Page 2 : comparemela.com

Bridging the Gap: Geriatric Assessment vs Routine Provider Evaluation in Gastroesophageal Cancer Care

Efrat Dotan, MD, discusses routine provider assessment vs the utility of geriatric assessment in geriatric patients with gastroesophageal disease.

Fox chase cancer centerUnited statesEfrat dotanDivision of gastrointestinal medical oncologyTemple healthHematology oncology fellowship training programDepartment of hematology oncologyGastrointestinal medical oncologyOncology fellowship training programOx chase cancer centerGastrointestinal cancer

Dr Dotan on the Use of Geriatric Assessments to Identify Unique Challenges in GI Cancer

Efrat Dotan, MD, discusses the use of geriatric function assessments in elderly patients with gastroesophageal cancer.

Efrat dotanDepartment of hematology oncologyHematology oncology fellowship training programFox chase cancer centerMedical oncologyOncology fellowship training programCancers symposiumshowedOnclive tvAsco gi

Dr Borghaei on Determining Treatments Utilizing Biomarker Testing in NSCLC

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.

Edmundm dunnHossein borghaeiDepartment of hematology oncologyDivision of thoracic medical oncologyFox chase cancer center at temple healthThoracic medical oncologyImmune monitoring facilityThoracic oncologyFox chase cancer centerTemple healthPer new york lung cancer symposiumLung cancer

IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

United statesFox chaseUniversity of pennsylvaniaNew yorkEdmundm dunnHossein borghaeiMerck celgeneDepartment of hematology oncologyCart programThoracic oncology at fox chase cancer centerDivision of thoracic medical oncologySafety monitoring board for university of pennsylvaniaBoehringer ingelheimAnnual new york lung cancers symposiumThoracic medical oncologyImmune monitoring facility

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesHong kongQian jiangJianyong liJianxiang wangPrnewswire ascentage pharmaHuafeng wangElias jabbourXiaojun huangJie jinKeshu zhouSikander ailawadhiXiaoyuan gongYifan zhaiLiposome mitoxantrone